Connect with us


Post-Wonderland Debrief: Mindset Pharma

The article Post-Wonderland Debrief: Mindset Pharma was originally published on Microdose.

Running from November 8-9, 2021 in Miami, Wonderland was an…



The article Post-Wonderland Debrief: Mindset Pharma was originally published on Microdose.

Running from November 8-9, 2021 in Miami, Wonderland was an impressive collection of scientists and researchers, investors and entrepreneurs, therapists and patients, government officials, and media — all championing the growth of the psychedelic medicine industry.

From heavyweight celebrities like Mike Tyson, to the industry’s top companies and insiders, Wonderland was the sector’s largest in-person event. The psychedelic medicine industry has officially arrived and we’re proud to be a part of it.

Pulling off such a massive undertaking wouldn’t be possible without the support of our sponsors, they are crucial to both the Wonderland event and the future of the psychedelic medicine industry.

Here’s a summary of Platinum Sponsor Mindset Pharma and their participation at Wonderland.

In addition to their generous financial support, Mindset Pharma also participated in important industry panels:

“Beyond Psilocybin: New Frontiers in Psychedelic Drug Design”

Mindset’s novel drug development was discussed by CEO James Lanthier and Joseph Araujo, Chief Science Officer


CEO James Lanthier at Wonderland
Mindset Pharma presenting at Wonderland

James Lanthier, CEO

A seasoned technology executive with strong expertise in corporate finance, public markets and M&A. Most recently, Mr. Lanthier was a co-founder and CEO of Future Fertility, an innovative early stage developer of AI applications for human infertility. As a C-Suite executive, Mr. Lanthier has assisted in the growth and successful exit of numerous technology-enabled businesses through the public markets, including Mood Media, the world’s largest in-store media provider.

Joseph Araujo, Chief Science Officer, InterVivo Solutions, Mindset Pharma

Joseph has dedicated his career to the application of science to ultimately improve the lives of people with health and medical needs. As President and CEO of InterVivo Solutions, Joseph is focused on optimizing the translational value of InterVivo’s services to facilitate the development and approval of novel drugs and therapeutics. Joseph continues to be closely involved in projects utilizing, characterizing and developing the aged dog as a natural model of age-related human diseases. Joseph is a strong proponent for the use of validated natural and/or translational animal models in drug discovery and in collaborative development of models. His scientific background includes graduate training in behavioral pharmacology and neuroscience at the University of Toronto, 40 refereed publications and several invited international presentations.

About the sponsor:

Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.

Read More